following a full submission
eribulin (Halaven®) is not recommended for use within NHS Scotland.
Indication under review: eribulin monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.
In a randomised, phase III, open-label study eribulin-treated patients had 2.5 months additional survival compared to the comparator, treatment of physicians choice, which included a range of single agent chemotherapy treatments.
The submitting company did not present a sufficiently robust economic analysis to gain acceptance by SMC
Download detailed advice202KB (PDF)
Medicine details
- Medicine name:
- eribulin mesylate (Halaven)
- SMC ID:
- 726/11
- Indication:
- For the treatment of patients with locally advanced breast cancer (LABC) or metastatic breast cancer (MBC), who have progressed after at least two chemotherapeutic regimens for advance disease.
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 October 2011